Quick Start — MSA at a glance

MSA (Multiple System Atrophy) combines Parkinsonism, autonomic failure, and cerebellar or pyramidal dysfunction in varying combinations
Two main subtypes: MSA-P (parkinsonism dominant) and MSA-C (cerebellar dominant)
Responds poorly to levodopa unlike typical Parkinson’s disease
Autonomic symptoms (orthostatic hypotension, urinary retention, REM sleep behavior disorder) are often the most disabling features
No disease-modifying therapy currently approved; management is symptom-focused with a multidisciplinary team
Median survival 6–10 years from onset; meticulous care improves quality of life substantially

1. The Alpha-Synuclein Family of Diseases

Parkinson’s disease (PD), Dementia with Lewy Bodies (DLB), Multiple System Atrophy (MSA), and Pure Autonomic Failure (PAF) belong to one family, the alpha-synucleinopathies. In each, a protein called alpha-synuclein misfolds, clumps together, and damages nerve tissue. They share that biology — but where the protein builds up, and in which cells, determines how each disease behaves, how fast it moves, and which treatments help. Getting the right label is not academic: it changes the prognosis, the medicines worth trying, the procedures to avoid, and how soon to plan for support.

One distinction sits at the heart of this guide. In Parkinson’s and DLB, the protein clumps form mainly inside neurons (nerve cells), where they are called Lewy bodies. In MSA, the clumps form mainly inside oligodendrocytes — the brain’s support cells that insulate nerve fibers — where they are called glial cytoplasmic inclusions. Because those support cells are spread across many systems, MSA damages movement, balance, the autonomic nervous system, and breathing more or less at once. That is why MSA is a different disease from Parkinson’s, not simply a worse version of it.

The Alpha-Synucleinopathies at a Glance

Disease	What Stands Out	Typical Course
Parkinson’s Disease (PD)	Slowness, stiffness, often a resting tremor; usually a strong, lasting response to levodopa. Non-motor symptoms (constipation, smell loss, mood, sleep) common.	Generally slow. Many people maintain meaningful function for 15–25 years with modern, expert care.
Dementia with Lewy Bodies (DLB)	Prominent thinking changes early — fluctuating alertness, visual hallucinations, REM sleep behavior disorder — with milder parkinsonism.	Moderate; cognitive decline is the main driver.
Multiple System Atrophy (MSA)	Early, severe autonomic failure (blood pressure, bladder, breathing) plus either parkinsonism (MSA-P) or cerebellar ataxia (MSA-C). Poor or brief levodopa response.	Faster than PD. Median survival is commonly cited at roughly 6–10 years from symptom onset, with wide individual variation.
Pure Autonomic Failure (PAF)	Autonomic failure (notably orthostatic hypotension) without prominent movement or cognitive features. A minority of cases later evolve toward PD, DLB, or MSA.	Usually the most slowly progressive of the group.

The one idea to carry forward. Typical Parkinson’s often allows many good years and responds well to standard medicine. MSA progresses faster and leans far more heavily on autonomic care, safety, and early planning. DLB centers on cognition and carries a specific medication danger. PAF is the slowest. All are helped by expert, multidisciplinary care — and in the faster conditions, that care matters most when it starts early.

2. Stage A — Early Parkinson’s Disease

This section is for people with, or being evaluated for, typical Parkinson’s disease in its early years. If the diagnosis is MSA, much of the foundational advice here — exercise, sleep safety, bowel care — still applies, but skip to Section 4 for the MSA-specific pathway.

Recognizing Early Parkinson’s

Parkinson’s disease happens when dopamine-producing cells in a region of the brain gradually decline. As dopamine falls, movement becomes slower, stiffer, or shaky. But Parkinson’s often announces itself first through non-motor symptoms, sometimes years before tremor or stiffness:

Loss of smell (anosmia) — a common, often-overlooked early feature.
REM sleep behavior disorder (RBD) — acting out dreams, with movement or vocalization during sleep. Isolated RBD is a recognized forerunner of PD, DLB, or MSA.
Constipation — frequently present well before motor symptoms.
Mood changes — depression and anxiety can precede the diagnosis.

The classic motor signs are slowness (bradykinesia), stiffness (rigidity), a resting tremor that is often on one side at first, and changes in balance and posture.

Starting Treatment: Levodopa and the Early Medicines

Levodopa, given with carbidopa, is the most effective medicine for Parkinson’s motor symptoms and is considered the gold standard. The brain converts levodopa into the dopamine it is missing. An older worry — that levodopa should be “saved for later” — is not supported by the evidence; when symptoms are affecting daily life, delaying effective treatment simply deprives a person of good function. Because dietary protein competes with levodopa for absorption, it is often taken 30–60 minutes before meals.

Other early options include MAO-B inhibitors (modest benefit, simple once-daily dosing) and dopamine agonists. Dopamine agonists can be useful, particularly in younger patients, but carry an important risk: impulse-control disorders — compulsive gambling, shopping, eating, or sexual behavior — as well as sudden daytime sleepiness. Families should know to watch for these and report them, as they typically improve when the medicine is reduced.

Exercise Is Core Treatment, Not an Extra

In Parkinson’s, exercise is one of the most powerful interventions available. High-intensity aerobic exercise in particular has evidence for improving motor symptoms, though whether it definitively slows the underlying neurodegeneration is still being studied. A reasonable early-PD target is roughly 150 minutes per week of moderate-to-vigorous aerobic activity, plus strength training about twice weekly and daily balance and large-amplitude movement practice. Structured programs — large-movement physical therapy, voice therapy, boxing-style and dance-based classes — have a strong following and good rationale.

Early PD versus MSA — an important contrast on exercise. In typical Parkinson’s, high-intensity upright exercise is encouraged. In MSA, exercise must instead be adapted for blood-pressure safety, favoring seated and recumbent activity (see Section 7). If you are not certain which diagnosis applies, ask — the right exercise prescription depends on it.

Early Non-Motor Care

From the start, good Parkinson’s care attends to more than movement: screening for and treating depression and anxiety; making the bedroom safe and treating RBD; managing constipation proactively; checking blood pressure lying and standing (orthostatic hypotension can occur even in early PD); and a baseline cognitive check. Building a care team early — a movement-disorders neurologist, a knowledgeable primary care physician, and therapists — pays dividends for years.

Questions to ask in early Parkinson’s

“Are you confident this is typical Parkinson’s, or could it be an atypical parkinsonism such as MSA? What features point you one way or the other?”
“Should I start levodopa now, and at what dose and timing?”
“If we use a dopamine agonist, what impulse-control changes should my family watch for?”
“What exercise should I be doing, and how do I do it safely?”

3. Stage B — Motor Fluctuations and Advanced Parkinson’s

After some years of successful treatment, many people with Parkinson’s find that medicines no longer give the smooth, all-day benefit they once did. This section explains what changes and what options open up. It applies to typical Parkinson’s; the equivalent advanced therapies generally do not help MSA, as Section 9 explains.

Wearing-Off and Dyskinesia

Two changes commonly appear:

Wearing-off — the benefit of a levodopa dose fades before the next dose is due, so symptoms return between doses (“OFF” time).
Dyskinesia — involuntary, often dance-like or writhing movements, most commonly occurring when medication levels peak.

The first response is usually to adjust oral medicines: changing the timing or size of levodopa doses, adding a COMT inhibitor or MAO-B inhibitor to extend each dose, switching to an extended-release levodopa, or adding amantadine to reduce dyskinesia.

When oral medicines can no longer be balanced well, several device-aided options can deliver medication more steadily:

Levodopa-carbidopa intestinal gel — a levodopa gel pumped continuously into the small intestine through a tube placed in a minor procedure. It smooths fluctuations by bypassing the unpredictable emptying of the stomach.
Continuous subcutaneous levodopa-carbidopa infusion — a newer approach delivering levodopa under the skin around the clock through a small pump, FDA approved in late 2024. It provides steady delivery without abdominal surgery; the main drawback is infusion-site skin reactions.
Apomorphine — a fast-acting dopamine agonist used either as intermittent injections to rescue sudden OFF periods or as a continuous under-the-skin infusion.

Deep brain stimulation (DBS) places thin electrodes in precise brain targets to deliver continuous, adjustable electrical stimulation. In well-selected Parkinson’s patients it can substantially reduce OFF time and dyskinesia. It is not a cure and does not slow the disease; its benefit broadly mirrors the best response a person still gets from levodopa, so a clear levodopa response, intact thinking, and stable mood are part of good candidacy.

MR-guided focused ultrasound uses focused sound waves to create a precise lesion in a brain target, without an incision or implanted hardware. It is used mainly for medication-refractory tremor, is typically performed on one side, and produces a permanent (not adjustable) lesion.

Realistic expectations for advanced PD therapies. DBS, focused ultrasound, and infusion therapies can be genuinely life-changing for the right Parkinson’s patient — but they manage symptoms; they do not stop the disease. Many people are referred later than ideal; it is reasonable to ask about these options once fluctuations or dyskinesia limit daily life despite well-adjusted oral medicines.

Questions to ask in advanced Parkinson’s

“Am I entering the window where DBS, focused ultrasound, or an infusion therapy should be discussed?”
“Given my age, thinking, and overall health, which option carries the best balance of benefit and risk for me?”
“What does the evaluation involve, and how long does it take?”

4. Multiple System Atrophy: How It Differs and the Red Flags

Multiple System Atrophy is the central focus of this guide. It is treated very differently from Parkinson’s, and getting the diagnosis right early is one of the highest-value steps a family can take. MSA is frequently mistaken for Parkinson’s in the first year or two, because the parkinsonian form can look very similar at the start. Roughly 1 in 10 to 1 in 5 people carrying a PD diagnosis are eventually found to have an atypical parkinsonism — most of this reclassification happens within the first two years of symptoms.

Features That Point Toward MSA Rather Than Typical PD

Feature	Typical Parkinson’s	Multiple System Atrophy
Response to levodopa	Strong and sustained, often for years	Poor, partial, or short-lived — benefit often fades within 1–2 years
Autonomic symptoms	Usually mild early, more prominent later	Early and severe — fainting on standing, bladder failure, erectile dysfunction, sometimes before movement symptoms
Speed of progression	Slow; years of preserved function	Faster; significant disability or a walking aid often within a few years of onset
Falls	Tend to occur later in the disease	Often early and frequent — more than 60% of people with MSA fall within the first three years
Speech and swallowing	Affected later	Affected earlier — slurred or strained speech, coughing with meals
Breathing	Stridor is rare	Stridor (a harsh, high-pitched sound on breathing in, often at night) can occur and is an important warning sign
Coordination	Cerebellar ataxia absent	In MSA-C, prominent ataxia — a wide-based, unsteady gait and clumsy hands
Other clues	—	Cold, dusky hands and feet; inspiratory sighs; marked forward neck bending; reduced facial expression out of proportion to other symptoms

Why an accurate label matters so much. An accurate diagnosis changes everything downstream: how long the road is likely to be, which medicines are worth a trial and which are not, whether procedures such as deep brain stimulation are appropriate (in MSA they are not), how aggressively to manage blood pressure and the bladder, when to protect swallowing, and when to involve palliative care. A poor or fading response to levodopa is itself one of the most useful diagnostic clues — it is information, not failure.

Questions to ask when MSA is suspected

“Do you think this is typical Parkinson’s, or could it be MSA? What are the red flags in our case?”
“Should we do formal autonomic testing and an MRI looking specifically for MSA changes?”
“If the diagnosis is uncertain, should we get a second opinion at a center that sees MSA regularly?”

5. Understanding MSA-P and MSA-C; Getting an Accurate Diagnosis

Multiple System Atrophy is a sporadic (non-inherited), progressive, adult-onset disease. It is described in two forms, based on which movement problem dominates; both share the same severe autonomic failure.

MSA-P (parkinsonian type) looks most like Parkinson’s at first — slowness and stiffness, sometimes an irregular tremor — but with a poor or brief response to levodopa and prominent early autonomic failure. In Western populations this is the more common form.
MSA-C (cerebellar type) begins with problems of balance and coordination: a wide-based, unsteady walk, clumsy hands, slurred or “scanning” speech, and abnormal eye movements. Parkinsonism may be mild or appear later. This form is comparatively more common in several East Asian populations.

MSA-P and MSA-C Compared

Feature	MSA-P (parkinsonian)	MSA-C (cerebellar)
Leading movement problem	Slowness, stiffness, sometimes irregular tremor	Ataxia — unsteady gait, limb incoordination
Speech	Slurred, may be strained	Slurred, “scanning,” cerebellar in quality
Autonomic failure	Early and severe in both types	Early and severe in both types
Levodopa response	Limited; partial in some, often fading	Generally minimal

A Note on Thinking and Memory

MSA was historically considered to spare cognition. More recent experience is more nuanced: while MSA does not usually cause the early, prominent dementia seen in DLB, a meaningful minority of people — roughly a third — develop frontal-executive difficulties (slowed mental processing, trouble with planning and multitasking), and a smaller number develop frank dementia, usually later in the course. Significant dementia within the first few years would prompt a clinician to reconsider whether the diagnosis is really MSA.

Getting an Accurate Diagnosis

There is rarely a single test that settles an MSA diagnosis. It is built over time from the pattern of symptoms, the neurological examination, the response (or lack of response) to levodopa, brain MRI, and tests of autonomic function. A specialist may reasonably need more than one visit to be confident.

Test	What It Looks At	What It Can and Cannot Tell You
Neurological exam and history	The pattern of movement, balance, autonomic, speech, and eye-movement findings over time	The foundation of diagnosis. A documented levodopa trial is part of this.
Levodopa trial	Whether parkinsonian symptoms improve on an adequate dose	A clearly poor or fading response supports an atypical syndrome such as MSA.
Brain MRI	Shrinkage and signal changes in the putamen, pons, and cerebellum	Certain patterns (a cross-shaped pontine sign, putaminal changes, cerebellar shrinkage) support MSA. A normal early MRI does not exclude it.
Autonomic testing (tilt-table, sweat testing)	How blood pressure, heart rate, and sweating respond to standardized challenges	Documents the degree and pattern of autonomic failure — central to the MSA picture.
Bladder ultrasound	How much urine remains after voiding (post-void residual)	Incomplete emptying is common in MSA and important to catch — retained urine causes infections and can harm the kidneys.
Alpha-synuclein seed amplification assay (SAA)	Detects misfolded alpha-synuclein in spinal fluid or skin	Confirms a synucleinopathy. Newer methods can begin to separate the MSA-type protein pattern from the PD/DLB type; this is a fast-evolving tool, not yet a routine, settled diagnostic test for MSA everywhere.
DaTscan (dopamine transporter imaging)	Loss of dopamine nerve endings in the brain	Abnormal in both PD and MSA, so it cannot separate the two. Useful mainly to distinguish these from essential tremor or drug-induced parkinsonism.
Cardiac MIBG scintigraphy	The sympathetic nerve supply to the heart	Tends to be reduced in PD, DLB, and PAF but relatively preserved in MSA — a helpful clue in difficult cases.
Sleep study	REM sleep behavior disorder, sleep apnea, and stridor	Important when noisy breathing or disrupted sleep is present; stridor needs prompt attention.

Honest Expectations About Prognosis

MSA progresses more quickly than typical Parkinson’s. Median survival from symptom onset is commonly cited in the range of roughly 6 to 10 years, but this is an average across many people and not a prediction for any one person; some live considerably longer with meticulous care, and survival beyond 15 years is documented. Earlier and more severe autonomic failure, early falls, and early swallowing or breathing problems tend to indicate a faster course. None of this changes the value of good care: multidisciplinary management, careful symptom control, attention to safety, and — where appropriate — clinical-trial participation can meaningfully improve how a person feels and functions.

Caregiver note — what the timeline means for you. In MSA the timeline is compressed compared with Parkinson’s, and the day-to-day autonomic symptoms — fainting, bladder accidents, swallowing and breathing changes — often create a heavier burden than the movement problems. Caregiver strain in MSA is substantial, measured in research at roughly twice that of typical Parkinson’s caregiving. That means you will need to learn autonomic safety earlier and more thoroughly, and build in respite care, home health support, and caregiver support groups from the start — not as luxuries, but as part of the medical plan.

6. Autonomic Symptoms — The Daily Work of MSA Care

In MSA the autonomic nervous system — the body’s automatic control of blood pressure, bladder, bowel, sweating, and sexual function — fails early and prominently. Managing it well is often the single largest factor in how safe and comfortable daily life is. This section is the practical core of living with MSA.

This is frequently the most disabling symptom. Blood pressure drops when the person stands, causing light-headedness, blurred vision, brain fog, neck or shoulder (“coat-hanger”) ache, fainting, and falls. Management begins with measures that do not involve medication:

Fluids and salt: increasing fluid intake (often toward 2–3 liters daily unless the care team advises otherwise) and, with the doctor’s approval, dietary salt, to support blood volume.
Compression: waist-high compression garments, and sometimes an abdominal binder, to reduce pooling of blood in the legs and abdomen.
Head-up sleeping: raising the head of the bed by roughly 30 degrees.
Rising in stages: sitting on the edge of the bed, then standing, then pausing before walking; avoiding sudden changes in position.
Avoiding triggers: large meals, hot baths, alcohol, and straining, all of which can worsen the drop.

When these are not enough, medications can be added — commonly midodrine, droxidopa, or fludrocortisone. These are decisions for the care team to individualize. An important practical point: the pressor medicines (midodrine and droxidopa) are morning and midday medicines. The last dose of the day should generally be taken no later than about 4–5 PM, so that they are not raising blood pressure overnight when the person is lying flat.

The supine hypertension balancing act. The same disease that drops blood pressure on standing can push it dangerously high when the person lies flat — this is called supine hypertension. The medicines used to raise standing blood pressure can worsen it. This is why the care team treats the standing and lying problems together as a balance, why the head of the bed is kept elevated, and why blood-pressure-raising medicines are stopped by late afternoon. Always check blood pressure both lying down and standing, and share the full picture with the doctor — never just the low numbers.

Caregiver note — the home blood pressure log. A simple home blood pressure monitor, used well, is one of the most useful things a family can own. The practical routine: take a reading lying down after about 5 minutes of rest, then again at 1 minute and 3 minutes after standing. Record the time of day and whether it was near a meal or a medication dose. As a rough orientation — to be individualized with the care team — the aim is generally a standing systolic pressure above about 90 and a supine systolic pressure below roughly 160–180. Bring the log to every appointment.

Bladder trouble is nearly universal in MSA and often appears early. Two problems frequently coexist: overactivity (urgency, frequency, leakage) and incomplete emptying (urine left behind after voiding). The second is easy to miss and important to catch, because retained urine causes infections and can harm the kidneys.

Ask for a bladder ultrasound to measure how much urine remains after voiding. This single measurement guides everything else.
Intermittent catheterization — using a thin catheter a few times a day — is often needed when emptying is incomplete. It sounds daunting but is usually far more manageable than families expect, and it protects the kidneys.
For overactivity, mirabegron is often preferred because, unlike older bladder medicines, it does not cloud thinking. Botulinum toxin injected into the bladder is an option for severe overactivity.
A referral to a urologist familiar with neurological disease is worth requesting early.

Constipation is common, often severe, and worth treating aggressively — for comfort, and because a sluggish gut interferes with medication absorption. Plenty of fluids, fiber (psyllium, ground flax), physical activity as able, and a daily osmotic laxative such as polyethylene glycol are the mainstays; the care team can add stronger agents if needed.

MSA can affect breathing, most distinctively through stridor — a harsh, high-pitched, sometimes crowing sound on breathing in, often during sleep. MSA can also cause sleep apnea and irregular breathing. This area needs active attention.

Report any new noisy, strained, or crowing breathing — awake or asleep — promptly. Recording the sound on a phone to play for the doctor is genuinely helpful.
An ENT (ear, nose, and throat) evaluation and a sleep study are usually needed.
Continuous positive airway pressure (CPAP) at night helps many people. In severe cases, a tracheostomy may be discussed; this is a goals-of-care conversation best had before a crisis.

MSA can reduce or disrupt sweating, affecting temperature regulation — staying cool and well hydrated matters, and hot tubs and saunas are best avoided. Erectile dysfunction is common in men and often early; treatments exist but must be used cautiously because they can worsen low blood pressure. Raise these openly with the care team; they are expected parts of the condition, not side issues.

Questions to ask about autonomic symptoms

“What should my standing blood pressure target be, and how do we balance that against high blood pressure when I lie down?”
“Can we start with the non-medication measures first? Which medication is right for me if those are not enough, and what time of day should I stop the last dose?”
“What is my post-void residual? Should I see a urologist, and might I need intermittent catheterization?”
“I have noisy breathing at night — do I need an ENT review and a sleep study?”

7. Movement, Falls, Speech, Swallowing, Exercise, and Nutrition

Because medicines do less for the motor symptoms of MSA than they do in Parkinson’s, hands-on rehabilitation and day-to-day safety carry proportionally more weight.

Falls and Mobility

Falls are the leading cause of injury-related hospitalization in MSA, and more than 60% of people with MSA fall within the first three years. Getting ahead of this is one of the most protective things a family can do.

Bring in physical and occupational therapy early, before a serious fall — for safe transfer training (bed, chair, toilet, car) and a home-safety assessment.
Obtain a rolling walker with a seat early. The seat matters: it lets the person sit immediately if blood pressure drops, turning a potential faint into a rest.
Make the home safer: remove loose rugs, improve lighting (especially on the route to the bathroom at night), install grab bars, add a raised toilet seat and a bedside commode.
A wheelchair evaluation is best done before it is urgently needed.

Speech and Swallowing

See a speech-language pathologist (SLP) at the first sign of quiet or slurred speech, or any coughing with meals — and ideally for a baseline assessment even before symptoms appear.

Expiratory muscle strength training (EMST) — exercises that strengthen the muscles used to cough, which protects the airway.
LSVT LOUD — an intensive voice therapy designed for Parkinson’s. It can be adapted for MSA, though expectations should be more modest.

A swallowing study (a video X-ray of swallowing) identifies which food and liquid textures are safe. Following the recommended textures — for example, thickened liquids if thin liquids are unsafe — substantially reduces the risk of aspiration pneumonia, a leading cause of hospitalization. Plan communication aids (apps, letter boards) early, while there is time to learn them.

Aspiration warning signs. Tell the care team promptly about: coughing or throat-clearing during or right after meals; a wet or gurgly voice after eating or drinking; fever in the hours after a meal; or recurrent chest infections. These can signal that food or liquid is entering the airway and that the swallowing plan needs to change.

Exercise — Adapted for MSA

Exercise remains valuable in MSA, but it must be adapted for blood-pressure safety. High-intensity upright exercise — helpful in Parkinson’s — can trigger dangerous blood-pressure drops and falls in MSA. A reasonable general target is around 150 minutes per week of activity, adapted as follows:

Favor seated and recumbent activity: a recumbent stationary bike is an excellent choice — a practical starting point is roughly 20–30 minutes at low-to-moderate intensity, about three times a week, with blood pressure checked before and after until the response is known.
Seated strength work with light weights or resistance bands, about twice weekly.
Gentle, supervised water therapy — provided blood pressure is stable and the pool is not too warm.
Seated tai chi or chair yoga for balance and flexibility.
Avoid: upright treadmill work at intensity, hot yoga and saunas, high-intensity interval training, and heavy weightlifting with breath-holding — all of which can crash blood pressure.

Nutrition

Nutrition deserves dedicated attention in MSA, because swallowing changes, slowed bowels, and reduced appetite can combine to cause unintended weight loss.

Hydration: generous fluid intake (often around 2–3 liters daily, unless the care team advises otherwise) supports blood pressure as well as bowel function.
Salt: when orthostatic hypotension is a problem, the care team may recommend a higher salt intake (commonly in the range of 3–5 grams per day) — this should always be confirmed with the physician.
Protein and levodopa: for the minority of MSA-P patients who get real benefit from levodopa, dietary protein can compete with its absorption; spacing levodopa from protein-heavy meals can help.
Weight monitoring: weigh regularly and report steady weight loss. Early involvement of a dietitian helps maintain nutrition.

Caregiver note — mealtimes and safety. Make mealtimes calm and unhurried. Keep the person fully upright while eating and for 20–30 minutes afterward. Follow the speech pathologist’s texture recommendations even when they feel restrictive — they are there to prevent a dangerous pneumonia. Learn safe transfer techniques from the therapy team and use equipment (transfer board, gait belt, mechanical lift) rather than lifting with your back; a caregiver injury is a crisis for two people at once.

Questions to ask about movement, swallowing, and nutrition

“Can we get physical, occupational, and speech therapy referrals now, before problems are severe?”
“Should we do a baseline swallowing study, and what food and liquid textures are safe for me?”
“What exercise is safe for me given my blood pressure, and should I monitor it around exercise?”
“Should I see a dietitian, and how should we watch for weight loss?”

8. Medicines — What Helps and What to Be Cautious About

No medicine currently stops or reverses MSA. But several medicines genuinely help with symptoms, and — just as importantly — some medicines should be avoided because they can cause real harm. Medication management in MSA is as much about what to leave out as what to add.

No specific dosages are listed in the patient section of this guide. Medication dosing is highly individual and must be determined by the prescribing physician. The information below is for educational context only. Detailed dosing information for healthcare professionals is available in Part 2, Section 20.

Levodopa in MSA

Every person with suspected MSA-P deserves a proper, documented trial of levodopa. The care team will titrate the dose upward and sustain it long enough — generally around three months — to judge the response fairly, measuring it objectively rather than by impression. About one-third of people with MSA-P get some partial benefit, though it often fades within one to two years. If there is no meaningful benefit, the right course is to taper the medicine off slowly: stopping an ineffective drug is good care, not giving up.

Other Medicines for Symptoms

Beyond levodopa, treatment in MSA focuses on the autonomic and other symptoms covered throughout this guide: pressor medicines for low blood pressure, mirabegron for bladder overactivity, laxatives for constipation, melatonin for REM sleep behavior disorder, botulinum toxin for excess saliva in selected cases, and treatment of depression and anxiety. Amantadine is sometimes tried for stiffness and slowness, but its benefit in MSA is weak and inconsistent. Dopamine agonists (such as pramipexole and ropinirole) are generally avoided in MSA: they do little for MSA motor symptoms and can significantly worsen low blood pressure.

Medicines to avoid or use only with great caution in MSA:

Dopamine-blocking drugs: certain anti-nausea medicines (metoclopramide, prochlorperazine) and older antipsychotics (such as haloperidol) can rapidly and sometimes lastingly worsen parkinsonism. If an anti-nausea drug is needed, ask about safer alternatives such as ondansetron or domperidone.
Anticholinergic drugs: older bladder medicines (oxybutynin), sedating antihistamines (diphenhydramine), and some antidepressants can cloud thinking and worsen constipation.
Blood-pressure-lowering drugs and erectile-dysfunction medicines: can dangerously deepen orthostatic hypotension; any use must be reviewed carefully by the care team.

Keep an up-to-date medication list, and ask a pharmacist or the neurologist to review any new prescription — including those from other doctors — against this list.

Many people with MSA also take dietary supplements, or are tempted to. Supplements are not harmless in MSA — some interact with autonomic medicines or affect blood pressure. The Appendix at the end of this guide covers supplements in detail; please read it before starting anything, and tell the care team about everything being taken.

Questions to ask about medicines

“How will we run the levodopa trial — what dose, how long, and how will we measure whether it is working?”
“Are any of my current medicines on the caution list for MSA?”
“If I need something for nausea, which options are safe for me?”
“I take (or am thinking about) these supplements — are any a problem?”

9. Advanced Procedures: DBS and Focused Ultrasound

Families facing MSA sometimes hear about deep brain stimulation or focused ultrasound and wonder whether these could help.

DBS and focused ultrasound are not treatments for MSA. Deep brain stimulation (DBS) and MR-guided focused ultrasound are valuable for carefully selected people with typical Parkinson’s disease. They are not treatments for MSA. They work by acting on specific brain circuits, and their benefit tracks a person’s response to levodopa. In MSA the degeneration is widespread, the levodopa response is poor, and these procedures do not improve MSA symptoms, do not address autonomic failure, and carry real risk of worsening balance and speech. If someone with an MSA diagnosis is offered DBS or focused ultrasound, that is a strong reason to seek a second opinion at a center experienced with MSA and to re-examine the diagnosis.

One nuance, mentioned for completeness: there are early case reports of focused ultrasound being used to relieve a disabling tremor in a few people with the parkinsonian form of MSA. These are isolated reports under specialist evaluation, aimed only at tremor — not a routine treatment, and not something that changes the overall message above.

Questions to ask about procedures

“I understand DBS and focused ultrasound are not for MSA — is that right for my situation, and why?”
“If a procedure has been suggested, does that mean the diagnosis should be reconsidered?”

class="content-section" data-stage="stage-c">

10. Emerging and Repurposed Therapies — An Honest Look

Research into MSA is active, and it is natural to want to know what is coming. The honest headline first: no therapy has yet been proven to slow, stop, or reverse MSA — or, for that matter, typical Parkinson’s. Some approaches are genuinely promising; others have recently failed. Both kinds of news matter.

Therapies Under Active Study

The following are investigational and have not been proven effective. They are listed for informational awareness only and do not constitute recommendations. Eligibility for clinical trials should be discussed with the care team.

Amlenetug is an antibody designed to bind and clear misfolded alpha-synuclein. An earlier Phase 2 study (AMULET, NCT05104476) did not meet its main goal but showed an encouraging trend; a large Phase 3 trial (MASCOT; verify on ClinicalTrials.gov) has completed enrollment, with results expected around 2027. Investigational — not proven.
ATH434 is an oral medicine that redistributes iron in the brain to reduce alpha-synuclein clumping. A Phase 2 trial (NCT05109091) reported a meaningful slowing of decline at its lower dose — the strongest Phase 2 signal MSA has seen — but this is preliminary and needs a confirmatory Phase 3 trial. Promising but not yet established.
Emrusolmin is an oral medicine that directly blocks alpha-synuclein from clumping, currently in Phase 2 testing (NCT06568237), having received an FDA Fast Track designation in 2025.
Ambroxol, a repurposed medicine, is being studied to help the cells clear alpha-synuclein, mostly in Parkinson’s (NCT02941822); MSA-specific data are limited.
High-dose ubiquinol (CoQ10) showed a positive result in a Phase 2 trial in MSA (NCT02388295) and is now in Phase 3 testing. It is discussed further in the Appendix; it is not yet an established therapy.
Anti-alpha-synuclein vaccines are in early testing.

Approved Elsewhere — TRH / Protirelin for Cerebellar Ataxia (Japan)

Protirelin (a thyrotropin-releasing hormone analog) has been approved in Japan since 1985 for cerebellar ataxia in spinocerebellar degeneration (SCD). A second-generation TRH analog, taltirelin, was approved in Japan in 2000 for the same indication. Because MSA-C (cerebellar-predominant MSA) falls under the SCD umbrella, these drugs are technically available to MSA-C patients in Japan.

Protirelin is administered intravenously; taltirelin is oral (once daily).
The primary target is cerebellar ataxia — gait instability, limb incoordination, and speech difficulty.
Sources: CNS Drugs review.

Important caveats — limited and transient benefit in MSA-C. While TRH analogs are approved and used in Japan for SCD broadly, the evidence specifically for MSA-C is disappointing. A 2026 retrospective study found that protirelin’s benefit in MSA-C “may be confined to early disease stages” and described an “early but transient response with limited long-term benefit.” In practical terms: some MSA-C patients may notice short-term improvement in ataxia symptoms, but this tends to fade. The underlying disease progression is not slowed. (ScienceDirect 2026.)

What this means for patients. TRH therapy is available only in Japan and is not approved or marketed for MSA elsewhere. Even in Japan, neurologists experienced with MSA recognize that the benefit is modest and time-limited. This is not a reason to travel to Japan for treatment. If you or a family member has MSA-C and lives in Japan, discuss TRH with the treating neurologist — but set realistic expectations. The most promising disease-modifying approaches for MSA remain the investigational therapies listed above (particularly ATH434 and amlenetug).

Recent Disappointments

Two well-conducted trials recently failed, and it is important to know this: verdiperstat, an anti-inflammatory medicine, did not help in a large MSA trial (M-STAR, NCT03952806); and ampreloxetine, which was being tested for low blood pressure in MSA, did not meet its goal in its Phase 3 trial (CYPRESS, NCT05696717), and its development was stopped in early 2026. Separately, the antisense medicine ION464 was discontinued in 2025 — importantly, for strategic business reasons, not because of a safety or efficacy problem.

How to read trial news. Headlines and press releases tend to emphasize the positive. A treatment is only credibly “proven” once a large, randomized, placebo-controlled trial has met its pre-defined main goal and the results have been published and scrutinized. Until then, the honest description is “under study, not proven.” The safest way to access a promising investigational treatment is through a properly approved clinical trial — not through clinics selling unproven therapies. If a trial interests you, ask the care team whether you might be eligible.

11. Dementia with Lewy Bodies and Pure Autonomic Failure

This guide focuses mainly on Parkinson’s and MSA, but two other members of the alpha-synuclein family deserve dedicated sections, because they look and behave differently — and because Dementia with Lewy Bodies carries a specific, important safety warning.

Dementia with Lewy Bodies (DLB)

In DLB, the alpha-synuclein pathology affects thinking prominently and relatively early. The hallmark features are:

Fluctuating cognition — alertness and clarity that vary noticeably, sometimes within a single day.
Visual hallucinations — typically well-formed, recurrent, and often appearing early.
REM sleep behavior disorder — acting out dreams, frequently preceding other symptoms by years.
Parkinsonism — slowness and stiffness, usually milder than in Parkinson’s disease itself, and often appearing around or after the cognitive changes.

Critical safety warning in DLB — antipsychotic sensitivity. People with DLB can have severe, occasionally life-threatening reactions to antipsychotic medications — this is called neuroleptic sensitivity. Older (“typical”) antipsychotics such as haloperidol are particularly dangerous and should be avoided. If an antipsychotic is genuinely necessary, quetiapine or clozapine are generally preferred, used cautiously and under specialist guidance. Any family member or caregiver of someone with DLB should make sure every treating clinician, including emergency staff, knows about this sensitivity.

Medicines called cholinesterase inhibitors (such as rivastigmine, often given as a patch, and donepezil) can give modest help with the thinking symptoms of DLB and are frequently worthwhile. Levodopa may help the movement symptoms but is used carefully, since it can worsen hallucinations. DLB is distinguished from MSA by its early, prominent dementia and its less severe autonomic failure.

Caregiver note — living with hallucinations. When hallucinations are not frightening or dangerous, it is usually kinder and more effective to gently reassure and redirect than to argue about whether something is real — arguing rarely helps and often distresses. Ensure the environment is safe, keep rooms well lit, and tell the care team about new or worsening hallucinations, since they can sometimes be triggered by infections, other medications, or dehydration.

Pure Autonomic Failure (PAF)

Pure Autonomic Failure is, in a sense, autonomic failure on its own — orthostatic hypotension, bladder problems, and related symptoms — without the prominent movement or cognitive problems of Parkinson’s, MSA, or DLB. It is usually the most slowly progressive condition in this family, and many people live with it stably for a long time.

The important nuance is that a minority of people with PAF eventually develop features of PD, DLB, or MSA over a span of years — a process called phenoconversion. For that reason, people with PAF benefit from periodic neurological re-evaluation to catch any emerging motor or cognitive change early. Day-to-day management centers on the same autonomic care described in Section 6.

Questions to ask about DLB and PAF

(DLB) “Does everyone on the care team, including any emergency providers, know about antipsychotic sensitivity?”
(DLB) “Would a cholinesterase inhibitor help, and what should we watch for?”
(PAF) “How often should I be re-evaluated for any emerging movement or memory changes?”

12. For the Caregiver

Caring for someone with MSA is demanding work. The disease moves faster than typical Parkinson’s, the autonomic crises can be sudden, and the person’s thinking often remains clear while their body declines — which is emotionally hard for everyone. Research finds caregiver strain in MSA roughly twice that of Parkinson’s caregiving. This section is for you.

An Autonomic Crisis Cheat Sheet

Situation	What to Do Right Away	When It Is Urgent
Fainting or severe light-headedness	Help the person lie flat and raise their legs. Do not try to keep them sitting upright. Let blood pressure recover before slowly getting up.	Seek emergency care if consciousness does not return within a couple of minutes, if there is a head injury, or if it keeps recurring.
New noisy or strained breathing (stridor)	Record the sound on a phone. Sit the person upright. Contact the neurologist or ENT — do not wait for a routine appointment.	Seek emergency care for severe breathing difficulty or bluish lips.
Unable to pass urine	If trained in intermittent catheterization, follow your instructions. Otherwise contact the care team.	Go to emergency care for inability to urinate with abdominal pain, or with fever and confusion.
Choking during a meal	If the airway is blocked, perform the Heimlich maneuver. Keep the person upright.	Call emergency services for any inability to breathe.
Fever with confusion	Check for a urinary infection as a likely cause. Contact the care team.	Seek urgent care — infections can cause rapid decline in MSA.

Protecting Your Own Body

Transfers and lifting are where caregivers get hurt. Ask the therapy team to teach you proper transfer technique, and get the right equipment before you need it: a transfer board, a gait belt, a hospital bed, and — when lifting becomes heavy — a mechanical or ceiling lift. Set up the home with grab bars, a shower chair, a raised toilet seat, and a bedside commode.

Emotional Support and Preventing Burnout

Anticipatory grief — mourning losses as they unfold — is normal and does not mean you are not coping. Watch for the warning signs of burnout in yourself: sleep deprivation, irritability with your loved one, neglecting your own health, withdrawing from friends. These are signals to get help, not character flaws.

Use respite care. In-home respite and adult day programs are medical tools, not indulgences. Arrange them before you are exhausted.
Join an MSA-specific support group. MSA is rare, and connecting with others who understand it — through the MSA Coalition and similar organizations — helps in a way general groups cannot.
Keep your own medical care. An annual physical, depression screening, and attention to your own sleep and stress are part of the care plan. If you collapse, the whole plan collapses.

Caregiver note — a script for calling the clinic. When you call the clinic under stress, a clear, specific message gets a faster, more useful response. For example: “My spouse has MSA. There is new noisy breathing at night” — or new fainting, or inability to urinate, or choking with meals — “Is this urgent, and who should we see?” Keep a one-page summary ready — diagnosis, current medications and their timing, allergies, the neurologist’s contact, and your contact — to hand to any emergency provider.

13. International Options and Clinical Trials

MSA looks somewhat different around the world. The cerebellar form (MSA-C) is comparatively more common in several East Asian populations, while the parkinsonian form (MSA-P) predominates in Western countries. Access to autonomic-testing laboratories, MSA-experienced specialists, and clinical trials also varies considerably.

If clinical trials interest you, useful starting points include ClinicalTrials.gov, the MSA Coalition (United States), and the MSA Trust (United Kingdom). Internationally, research networks such as the European MSA Study Group and the Japanese MSA research consortium run trials and natural-history studies. Discuss eligibility with the care team: many trials seek people relatively early in the disease.

Geographic variation in MSA subtypes. MSA subtype distribution varies geographically: MSA-C (cerebellar predominant) is more common in Japan and East Asia, whereas MSA-P (parkinsonian predominant) predominates in Western populations. This is clinically relevant for diagnosis, prognosis counseling, and interpreting international research. Major MSA natural-history cohorts include the European MSA Study Group (EMSA-SG) registry and large Japanese cohorts. When reading trial results, note the study population — a trial conducted primarily in Japan may enroll a higher proportion of MSA-C patients, which can affect the applicability of findings to a Western MSA-P–predominant population, and vice versa.

A caution about unregulated “stem cell” clinics. Be very wary of clinics — often overseas, often cash-pay — that advertise “stem cell” or “regenerative” cures for MSA. These offerings are not supported by evidence, can cause serious harm, and divert families from real care and legitimate trials. The only appropriate route to cell-based therapies is through a properly approved, ethically reviewed clinical trial.

14. Specialty Centers and Resources

MSA is rare, and expert, multidisciplinary care makes a real difference. The directory below is organized by region to help families find experienced programs. Not every center listed runs an MSA-specific clinic, but all have movement-disorders or autonomic neurology expertise relevant to MSA care.

How to choose the right level of care.

Academic medical center or MSA-experienced program: Best for initial diagnosis confirmation, autonomic testing, clinical trial access, and complex medication management. Especially important when the diagnosis is uncertain, when symptoms are progressing rapidly, or when stridor or severe autonomic failure is present.
Community movement-disorders neurologist: Appropriate for ongoing follow-up once the diagnosis is established and a management plan is in place, particularly if the academic center is far away. Ideally in coordination with the specialist team.
VA Medical Center: Veterans with MSA should know that VA movement-disorders programs exist and can coordinate with academic centers. VA benefits may cover travel to specialty centers when local VA expertise is limited.
Telehealth: Many academic programs now offer telehealth follow-up for patients in rural or distant areas. Ask when scheduling.

Mountain West / Utah

The University of Utah Movement Disorders Program is the regional referral center for Parkinson’s disease and atypical parkinsonian disorders, including MSA. It operates as a designated Parkinson’s Foundation Center of Excellence. The program provides subspecialty evaluation by movement-disorders neurologists, characterization of levodopa response through structured trials, expert interpretation of brain MRI, in-house or affiliated physical, occupational, and speech therapy, social work and care navigation, and access to clinical trials.

U of U Movement Disorders / Neurosciences: 801-585-6387
Scheduling (Neurology): 801-585-7575
Fax for referrals: 801-585-2746
Location: Imaging and Neurosciences Center, Research Park, 729 Arapeen Drive, Salt Lake City, UT 84108.
New-patient visits are typically longer than routine appointments; bring prior MRI discs, a complete medication list, and an autonomic symptom diary or blood pressure log. Telehealth follow-up may be available for patients in rural Utah.

Because autonomic failure is central to MSA, the program’s Autonomic Physiology Laboratory is a particularly important resource. The laboratory performs tilt-table testing, quantitative sudomotor axon reflex testing (a sweat test), and cardiovascular reflex testing. This kind of objective autonomic testing is essential for a confident MSA diagnosis. Autonomic evaluations require a physician referral.

Other University of Utah Health resources relevant to MSA families:

University of Utah Health (main): 801-581-2121
Huntsman Mental Health Institute (HMHI): 801-583-2500 — mood, anxiety, and caregiver mental health support
Intermountain Health: 801-442-2000 — the other major health system in Utah; neurology and rehabilitation services across the Wasatch Front

A practical referral tip. When a primary care physician or general neurologist places a referral, asking them to mark it explicitly as “suspected atypical parkinsonism / MSA — needs autonomic workup” helps the request be routed and prioritized correctly, and signals that autonomic testing (tilt-table and sweat testing) should be part of the evaluation.

US National

For a second opinion, specialized autonomic evaluation, or clinical trial access, the following academic centers have established programs in autonomic neurology and/or MSA:

Mayo Clinic — Rochester, MN: 507-284-2511. Department of Neurology, Autonomic Disorders Center. One of the largest autonomic testing laboratories in the world.
Mayo Clinic — Scottsdale, AZ: 480-301-8000. Movement disorders and autonomic neurology. Closer option for Mountain West families.
Vanderbilt Autonomic Dysfunction Center — Nashville, TN: 615-322-5000. A leading center for autonomic failure research and clinical care, with extensive MSA experience.
NYU Langone Dysautonomia Center — New York, NY: 212-263-7225. Comprehensive autonomic evaluation and management.
Beth Israel Deaconess / Harvard — Boston, MA: 617-667-7000. Movement disorders and autonomic neurology programs.
University of Michigan — Ann Arbor, MI: 734-936-9070. Movement disorders program with autonomic expertise.
UCSF Movement Disorders and Neuromodulation Center — San Francisco, CA: 415-353-2273. Active MSA and atypical parkinsonism research.

Veterans

Veterans with MSA are eligible for specialized care through the VA system. Key resources:

George E. Wahlen VA Medical Center — Salt Lake City, UT: 801-582-1565. Neurology services; can coordinate with the University of Utah Movement Disorders Program for complex cases.
VA Parkinson’s Disease Research, Education, and Clinical Centers (PADRECCs): Six national VA centers of excellence for movement disorders, located in Philadelphia, Houston, Los Angeles, San Francisco, Portland (OR), and Richmond (VA). Ask your VA primary care provider for a PADRECC referral if MSA is suspected.
VA Community Care: When local VA neurology lacks movement-disorders subspecialty expertise, veterans may be referred to academic medical centers through the VA Community Care program. Ask the VA care team about eligibility.

Canada

Major Canadian centers with movement-disorders and autonomic neurology expertise relevant to MSA:

Toronto Western Hospital — Movement Disorders Centre (University Health Network): 416-603-5800. One of the largest movement-disorders programs in North America, with active MSA research and autonomic testing.
Montreal Neurological Institute (The Neuro) — McGill University: 514-398-6644. Movement disorders and neurodegenerative disease research.
Vancouver Coastal Health — UBC Movement Disorders Clinic: 604-822-7764. Movement disorders evaluation and management; Pacific Parkinson’s Research Centre.
Sunnybrook Health Sciences Centre — Toronto: 416-480-6100. Harquail Centre for Neuromodulation; movement disorders program.
Ottawa Hospital — Parkinson’s and Movement Disorders Clinic: 613-798-5555. Regional referral for eastern Ontario.

International

For families outside North America, or those seeking additional opinions:

United Kingdom:
- National Hospital for Neurology and Neurosurgery (Queen Square) — London: +44 20 3456 7890. Part of UCLH; one of the world’s leading neurology centers. Autonomic Unit and movement disorders service.
- Autonomic Unit, St Mary’s Hospital — Imperial College London: +44 20 3312 6114. Specialist autonomic testing and management.
Europe:
- Medical University of Innsbruck — Austria: +43 512 504 0. Home of the European MSA Study Group (EMSA-SG); major MSA natural-history cohort and trial site.
- Charité — Universitätsmedizin Berlin, Germany: +49 30 450 50. Movement disorders and autonomic neurology; emrusolmin (anle138b) trial site.
Japan / Asia-Pacific:
- Hokkaido University Hospital — Sapporo: +81 11 716 1161. Leading MSA research program; ubiquinol Phase 3 trial site. Longest clinical experience with droxidopa (approved in Japan since 1989).
- National Center of Neurology and Psychiatry (NCNP) — Tokyo: +81 42 341 2711. National referral center for rare neurological diseases including MSA.

Community Support

The MSA Coalition (US) offers MSA-specific support groups, caregiver resources, educational webinars, and maintains a physician directory. The MSA Trust (UK) provides equivalent support for families in the United Kingdom. Local Parkinson’s organizations in Utah and elsewhere provide support groups and adapted exercise classes that also serve MSA families. Utah’s aging and disability resource services can help with respite care, home health, and equipment.

15. Advance Care Planning and Palliative Care

Planning ahead is one of the most loving and practical things a family can do. It is not giving up — it is making sure that, whatever comes, care reflects the person’s own values and that decisions are not made in crisis. Because MSA moves faster than typical Parkinson’s, this work should start early.

Palliative Care — Earlier Than Most People Expect

Palliative care is specialized care focused on comfort, symptom relief, and support for the patient and family. It is not the same as hospice or end-of-life care and is entirely appropriate alongside active treatment. In MSA, a palliative care consultation is reasonably requested at diagnosis or within the first 6–12 months. Early palliative involvement improves quality of life and does not shorten survival.

Documents to Put in Place

Advance directive (living will) — records the person’s wishes about medical interventions.
Durable power of attorney for healthcare — names a trusted person to make medical decisions if the patient cannot.
POLST (Physician Orders for Life-Sustaining Treatment) — a medical order, signed by a physician, that guides emergency personnel. Utah has its own forms for these documents.

Trigger Points for Revisiting the Plan

Advance care planning is not a single conversation but a series of check-ins. Each of the following milestones is a natural prompt to revisit goals of care with the team:

At the time of diagnosis.
At the first significant fall or first hospitalization.
When swallowing becomes unsafe.
When stridor develops.
When mobility comes to require a wheelchair.

Conversations Worth Having Early

While communication is still strong, it helps to discuss, gently and without pressure, the decisions that may arise later: breathing support if stridor becomes severe; whether a feeding tube would align with the person’s values if swallowing becomes unsafe; and the preferred place of care. Having these conversations ahead of time spares the family from making wrenching choices in an emergency.

Caregiver note — you are part of the care plan. Palliative care teams support the family, not only the patient. Use that support. Ask about counseling, respite, and bereavement resources before they feel urgent. Caring for someone with MSA is a marathon; pacing yourself, and accepting help, is what makes it possible to be there for the whole journey.

Closing thought for Part 1. An accurate diagnosis and proactive, well-organized care — above all, careful attention to autonomic safety in MSA — genuinely change how this journey feels. The days still hold connection, meaning, and moments of joy. A good plan, made early and revisited often, helps protect them. You do not have to know everything at once; you only have to take the next informed step, with a team beside you.

16. Pregnancy, Family Planning, and Reproductive Health

Parkinson’s disease and the broader synucleinopathy family primarily affect people in their 50s, 60s, and beyond, but young-onset Parkinson’s disease (YOPD, defined as symptom onset before age 50) accounts for 10–15% of all PD patients, and these individuals are frequently in their reproductive years at the time of diagnosis. Pure Autonomic Failure (PAF) can also present in younger adults. This section addresses the real questions that arise for younger patients and for families of any age who are navigating this diagnosis.

For women with young-onset PD who are pregnant or considering pregnancy, the most common treatment question is whether levodopa (carbidopa/levodopa, the most effective PD medication) can be continued during pregnancy. Levodopa crosses the placenta; in animal studies at high doses, levodopa has been associated with skeletal and visceral abnormalities in rodent offspring, but human registry data from the UK Parkinson’s Disease Register and several European case series have not identified a clear pattern of fetal malformation or neonatal harm from therapeutic doses used in human pregnancy. Most movement disorder neurologists recommend continuing levodopa if discontinuation would leave the patient with uncontrolled PD symptoms, given the potential risks of undertreated disease (falls, aspiration, immobility, severe muscle rigidity, and the stress response of undertreated pain on the fetus) likely exceed the theoretical risks of continued therapy. This should be discussed with a maternal-fetal medicine specialist and individualized to the patient’s disease stage and symptom severity.

Dopamine agonists (pramipexole, ropinirole, rotigotine) used in early YOPD are generally recommended to be tapered and discontinued before conception where possible, given animal teratogenicity data, though the human evidence base is limited. MAO-B inhibitors (rasagiline, selegiline, safinamide) are also generally held during pregnancy given limited human safety data. Decisions about continuation of any PD medication in pregnancy should involve a three-way conversation between the patient, their movement disorder neurologist, and a maternal-fetal medicine specialist at a high-risk obstetric center.

Autonomic effects during normal pregnancy (progesterone-mediated vasodilation, third-trimester compression of the inferior vena cava in the supine position) already cause some degree of blood-pressure drop in all pregnant women. In patients with established neurogenic orthostatic hypotension (as in MSA or advanced PD autonomic failure), these physiological changes compound the existing OH and require more vigilant management: increased hydration targets, elevation of the head and right hip in the third trimester (to reduce vena cava compression), and careful review of pressor medications with the obstetric team. Midodrine and fludrocortisone are not formally studied in pregnancy and carry theoretical fetal risks from placental vasoconstriction; their use in pregnancy requires specialist consultation.

Young-onset PD has a substantially higher genetic contribution than typical late-onset PD. The most common genetic forms of YOPD involve mutations in PARK2/Parkin (most common recessive form, onset often 20s–40s), PINK1 (second most common recessive, similar onset), DJ-1/PARK7 (rare recessive), and LRRK2 G2019S (autosomal dominant, variable penetrance, most common in Ashkenazi Jewish and North African populations). If a patient has YOPD with no clear sporadic risk factors (head trauma, pesticide exposure, family history of older PD), genetic testing is strongly recommended, not only for personal risk understanding but for family planning purposes. Current genetic testing panels for Parkinson’s disease are available commercially (GeneDx, Invitae, Ambry, and others) and through academic movement disorder centers, and typically cover 20+ Parkinson’s-associated genes.

For patients who carry a known Parkinson’s-associated mutation and are considering pregnancy, preimplantation genetic testing for monogenic conditions (PGT-M) is available through fertility specialists and allows selection of embryos that do not carry the pathogenic variant before IVF transfer. Genetic counseling by a board-certified genetic counselor should precede any decision about PGT-M, as the discussion involves the penetrance of the specific variant (not all carriers develop PD), the ethical dimensions of embryo selection for a late-onset condition, and the alternatives (natural conception with prenatal testing, or acceptance of carrier status). Resources: the Michael J. Fox Foundation Gene Therapy Program and MJFF Parkinson’s Genetic Registry, the Parkinson’s Foundation Genetic Testing Initiative, and the National Society of Genetic Counselors referral service.

When the patient with MSA or PD is a partner or parent of reproductive-age adults, rather than being reproductive-age themselves, family planning considerations shift to the emotional, practical, and caregiver dimensions of adding a child to a family already navigating a serious neurodegenerative diagnosis. Partners and children of people with MSA or advanced PD often become primary caregivers; the physical and emotional demands of caregiving are already substantial and will intensify as disease progresses. Decisions about pregnancy in this context benefit from honest conversation with the care team about the projected disease trajectory over the next 5–10 years, the practical support network available, and the patient’s own wishes about participating in childcare as the child grows.

Practical resources for young caregivers and families: the MSA Coalition (multiplesystematrophy.org), the Parkinson’s Foundation Helpline (1-800-4PD-INFO, 1-800-473-4636), the National Alliance for Caregiving, and the Well Spouse Association all offer support specifically designed for partners and family members navigating neurodegenerative disease. Respite care, social work consultation, and palliative care team involvement are appropriate resources to introduce early—before the caregiver is in crisis rather than after.

Questions to Ask Your Doctor (Reproductive Health & Genetics)

Should I get genetic testing for Parkinson’s-associated gene mutations? If so, which test is most appropriate for my situation?
If I carry a PD-associated mutation, what are the options for family planning, including preimplantation genetic testing?
Which of my current PD or autonomic medications are considered safest to continue if I become pregnant?
How will pregnancy affect my orthostatic hypotension symptoms, and how do we manage that safely?
Can you refer me to a high-risk obstetric specialist (maternal-fetal medicine) for pre-conception counseling?

Appointment Checklist — Consolidated Questions

Print this checklist, mark the questions that apply, and bring it to appointments — ideally with a second person to take notes.

Diagnosis and Prognosis

Is this typical Parkinson’s, or could it be MSA or another atypical parkinsonism? What are the red flags in our case?

Should we do formal autonomic testing and an MRI looking specifically for MSA changes? Would a seed amplification assay help?

If MSA, is it the MSA-P or MSA-C type, and what does that mean for us?

What is the realistic picture for the next one to two years?

Should we get a second opinion at a center that sees MSA regularly?

Medicines

How will we run the levodopa trial — what dose, how long, and how will we measure whether it works?

Are any of my current medicines on the caution list for MSA?

If I need something for nausea, which options are safe?

I take (or am considering) these supplements — are any a problem?

Autonomic and Daily Symptoms

What should my standing blood pressure target be, and how do we balance it against high blood pressure lying down?

What time of day should I take — and stop — my blood-pressure medicines?

What is my post-void residual? Should I see a urologist, and might I need intermittent catheterization?

I have noisy breathing at night — do I need an ENT review and a sleep study?

Therapy, Procedures, and Trials

Can we get physical, occupational, and speech therapy referrals now?

Should I have a baseline swallowing study? What food and liquid textures are safe?

What exercise is safe given my blood pressure?

I understand DBS and focused ultrasound are not for MSA — is that right for me, and why?

Are there clinical trials I might be eligible for?

Care Planning and Support

Can we involve palliative care now for symptom support and planning?

When should we complete an advance directive, durable power of attorney, and POLST?

What respite care, home health, and caregiver support exist locally?

When should we discuss feeding tube and breathing support preferences?

Part 2 — Clinical Guide for Healthcare Professionals

Intended for qualified healthcare professionals. This section is decision-support synthesis, not a substitute for clinical judgment, primary guideline documents, or specialist consultation. Dosing, off-label use, trial status, and regulatory approvals must be verified against current prescribing information and primary literature before application. Evidence is current to early 2026 and the alpha-synucleinopathy field evolves rapidly.

17. Differential Diagnosis Across the Synucleinopathy Spectrum

The early clinical features of PD, MSA-P, MSA-C, DLB, and the principal non-synuclein mimic, progressive supranuclear palsy (PSP), overlap substantially. A structured, multi-domain approach, supplemented by biomarkers, is required.

Feature	PD	MSA-P	MSA-C	DLB	PSP
Initial motor presentation	Asymmetric rest tremor, rigidity, bradykinesia	Symmetric akinetic-rigid syndrome, axial rigidity	Gait and limb ataxia, incoordination	Cognitive decline before/with mild parkinsonism	Early postural instability, backward falls
Levodopa response	Excellent, sustained	Poor, transient, or absent	Minimal to none	Variable, typically modest	Poor to none
Autonomic failure	Later, mild–moderate	Early, severe, progressive	Early, severe, progressive	Moderate, variable	Mild or absent
Cerebellar signs	Absent	Absent or late/transient	Present, early, defining	Absent	Absent
Cognition	Executive function preserved early; late dementia	Mild executive dysfunction; early dementia an exclusion	Mild executive dysfunction; early dementia an exclusion	Early fluctuating cognition, visual hallucinations	Early frontal/executive dysfunction, apathy
Oculomotor	Mild hypometric saccades	Mild hypometric saccades, square-wave jerks	Gaze-evoked nystagmus, impaired pursuit	Variable	Vertical supranuclear gaze palsy
MRI	Often normal early	Putaminal atrophy, hypointense rim, increased diffusivity	Pontine “hot cross bun,” MCP atrophy	Nonspecific	Midbrain atrophy (“hummingbird”)
Cardiac MIBG	Reduced	Relatively preserved	Relatively preserved	Reduced	Preserved

Red flags favoring MSA over PD (several together warrant specialist review): early severe progressive autonomic failure; poor/unsustained levodopa response after adequate trial; early postural instability and falls (~3 years); rapid progression; inspiratory stridor or sighs; severe early dysarthria or dysphagia; disproportionate antecollis; cold, dusky extremities; pseudobulbar affect; and combined cerebellar and parkinsonian signs.

18. MDS 2022 Diagnostic Criteria for MSA

The Movement Disorder Society revised the clinical diagnostic criteria for MSA in 2022 (Wenning et al., Mov Disord 2022), introducing a tiered framework.

Category	Core Requirements	Notes
Neuropathologically established MSA	Post-mortem demonstration of widespread, abundant glial cytoplasmic inclusions with striatonigral and/or olivopontocerebellar neurodegeneration.	Diagnostic gold standard.
Clinically established MSA	Sporadic, progressive, adult-onset (>30 y). Autonomic dysfunction (neurogenic OH and/or urogenital failure) plus poorly levodopa-responsive parkinsonism or a cerebellar syndrome. Plus ≥2 supportive features and ≥1 MRI marker.	Highest clinical specificity.
Clinically probable MSA	Sporadic, progressive, adult-onset. At least two of: autonomic dysfunction, parkinsonism, cerebellar syndrome — plus ≥1 supportive feature.	MRI markers supportive but not mandatory.
Possible prodromal MSA	Research category: e.g., polysomnography-proven RBD, neurogenic OH, or urogenital failure with subtle, non-diagnostic motor signs.	For research and trial enrichment; not a clinical diagnosis.

Supportive features span motor and non-motor domains: rapid progression, early postural instability, craniocervical dystonia (antecollis, orofacial dyskinesia), severe dysarthria or dysphagia, inspiratory stridor, inspiratory sighs, cold/discolored extremities, and pathologic laughter or crying.

Exclusion features include a substantial persistent levodopa response, dementia within 3 years of motor onset, recurrent early visual hallucinations, downgaze supranuclear palsy, and unexplained anosmia on objective testing.

19. Biomarkers and Ancillary Investigations

No single biomarker establishes an MSA diagnosis; biomarkers refine probability and support differentiation within a structured clinical assessment.

Investigation	Finding in MSA	Practical Role and Caveats
Alpha-synuclein SAA (CSF or skin)	Positive; MSA-type seeds show distinct aggregation kinetics	Confirms synucleinopathy. Subtype discrimination advancing; sensitivity for MSA-type seeds (~80–90%) lower than for PD/DLB Lewy-type seeds (~95%). Skin biopsy SAA emerging as less invasive alternative. Not yet a settled stand-alone differential test.
Cardiac MIBG scintigraphy	Relatively preserved (preganglionic/central lesion)	Useful discriminator: reduced in PD, DLB, and PAF (postganglionic denervation). Confounded by diabetes, ischemic heart disease, and certain medications.
Neurofilament light chain (NfL)	Elevated relative to PD; comparable to PSP	Prognostic and trial-enrichment biomarker. Serum NfL >50–60 pg/mL favors atypical diagnosis; >100 pg/mL associated with rapid MSA progression. Non-specific.
Brain MRI (3T preferred)	MSA-P: putaminal atrophy, hypointense rim. MSA-C: pontine “hot cross bun,” MCP atrophy	Supportive when present; required at “clinically established” level. Normal early MRI does not exclude MSA.
DaTscan (DAT-SPECT)	Abnormal (reduced uptake)	Confirms degenerative parkinsonism; cannot distinguish MSA from PD.
Autonomic reflex testing	Neurogenic OH with blunted compensatory heart-rate rise	Confirms and characterizes autonomic failure. Beat-to-beat tilt-table is reference method.
Polysomnography with laryngoscopy	Stridor, sleep-disordered breathing, RBD	Essential when stridor is suspected.

Neurogenic orthostatic hypotension is defined as a sustained fall of ≥20 mmHg systolic or ≥10 mmHg diastolic within 3 minutes of standing or head-up tilt, with an inadequate compensatory heart-rate rise (ΔHR/ΔSBP <0.5 bpm/mmHg). The MDS 2022 MSA criteria adopted this ≥20/10 mmHg threshold, replacing the older 2008 ≥30/15 mmHg requirement to improve diagnostic sensitivity.

COQ2 note. COQ2 variants (notably V393A) are associated with sporadic MSA in East Asian populations and provide a pharmacogenomic rationale for ubiquinol supplementation. Routine genetic testing is not part of the standard clinical workup.

20. Autonomic Assessment, Dosing, and Supine Hypertension

Domain	Assessment	Management and Dosing
Neurogenic OH	Supine and standing BP/HR; tilt-table	Non-pharmacologic first: volume (2–3 L/day), sodium liberalization, waist-high compression, head-up bed (~30°), staged rising. Pharmacologic: midodrine 2.5–10 mg TID (last dose by ~4 PM); droxidopa 100–600 mg TID; fludrocortisone 0.1–0.3 mg/day; pyridostigmine 30–60 mg TID as adjunct.
Supine hypertension	Supine and overnight BP; ambulatory monitoring	Head-up positioning; avoid late-day pressors. If severe: short-acting nocturnal agents — losartan 25–50 mg, nitroglycerin patch 0.1–0.2 mg/hr (removed AM), or hydralazine 10–25 mg at bedtime. Target supine SBP <160–180 without exacerbating morning OH.
Lower urinary tract	Post-void residual ultrasound; consider urodynamics	Overactivity: mirabegron 25–50 mg daily (preferred). Intradetrusor onabotulinumtoxinA 100–200 U for refractory overactivity (ensure CIC readiness). Retention (PVR >100 mL): clean intermittent catheterization.
Constipation	History, abdominal exam	Polyethylene glycol 17 g/day first-line; add prucalopride or lubiprostone for refractory cases.
Stridor / sleep-disordered breathing	Polysomnography, laryngoscopy	CPAP/BiPAP; ENT evaluation. Tracheostomy for severe, life-threatening cases after goals-of-care discussion. Independent risk factor for sudden death.
Sialorrhea	Clinical; coordinate with swallowing assessment	OnabotulinumtoxinA to parotid/submandibular glands (~25–50 U per side); glycopyrrolate 1–2 mg BID–TID; sublingual atropine drops.
RBD	History, polysomnography	Melatonin 3–12 mg at bedtime (first-line). Low-dose clonazepam 0.25–0.5 mg alternative — weigh fall risk. Bedroom safety measures.

21. Levodopa, Motor Management, and Advanced PD Therapies

For clinicians: A dedicated Clinical Reference Guide with expanded dosing tables, diagnostic algorithms, evidence grading, and drug-interaction matrices is available.

The Adequate Levodopa Trial in MSA

A formal, documented levodopa trial is mandatory before designating an MSA patient a non-responder.

Dose: titrate to at least ~1,000 mg/day of the levodopa component (not total tablet weight), as tolerated.
Duration: sustain the target/tolerated dose for a minimum of ~3 months.
Objective assessment: quantify with MDS-UPDRS Part III or UMSARS motor examination before and after, supplemented by timed walk and patient/caregiver diary.
Expected response: roughly one-third of MSA-P patients show a partial response, typically waning within 12–24 months; MSA-C rarely benefits.
Reasons a trial may fail spuriously: underdosing, poor adherence, protein interference, nausea, hypotension, delayed gastric emptying.
Discontinuation: if no documented objective benefit, taper and discontinue to avoid exacerbating OH and precipitating levodopa-induced orofacial dystonia.

Dopamine agonists are generally avoided (limited efficacy, OH exacerbation, impulse-control risk). Amantadine has weak, inconsistent evidence; if trialed, start 100 mg BID with renal dose adjustment.

22. Evidence and Dosing Tables

Evidence badges: STANDARD established, guideline-supported SUPPORTED reasonable evidence, narrower role LIMITED weak or inconsistent INVESTIGATIONAL under study, not proven NEGATIVE well-conducted trial showed no benefit

Therapy	Evidence	Dosing / Practical Notes
Carbidopa/levodopa (IR, ER, Rytary)	STANDARD	Most effective symptomatic therapy. Start 25/100 mg TID; titrate to effect. Protein timing matters.
Dopamine agonists	STANDARD	Early PD or adjunct. Screen for impulse-control disorders. Avoid in MSA.
MAO-B inhibitors	SUPPORTED	Modest symptomatic benefit; well tolerated.
COMT inhibitors	SUPPORTED	Reduce OFF time. Opicapone once daily.
Amantadine (IR / ER)	SUPPORTED	Reduces dyskinesia. Weak/inconsistent in MSA.
Device-aided (intestinal gel, SC foslevodopa-foscarbidopa, apomorphine infusion)	STANDARD	Advanced PD. Not for MSA.
DBS (STN / GPi)	STANDARD	Selected levodopa-responsive PD. Contraindicated in MSA.
MR-guided focused ultrasound (VIM)	SUPPORTED	Tremor-predominant PD/essential tremor. Contraindicated in MSA.

Agent	Rationale	Status	Evidence
Amlenetug (Lu AF82422) — MSA	Anti-alpha-synuclein mAb	Phase 2 AMULET (NCT05104476) missed primary; Phase 3 MASCOT (verify on ClinicalTrials.gov) enrolled, results ~2027	INVESTIGATIONAL
ATH434 — MSA	Iron-modulating small molecule	Phase 2 (NCT05109091): 48% relative slowing on modified UMSARS-I at 50 mg (p=0.02); Phase 3 planned	INVESTIGATIONAL
Emrusolmin (anle138b) — MSA	Oral alpha-synuclein aggregation inhibitor	Phase 2 (NCT06568237) ongoing; FDA Fast Track Sept 2025	INVESTIGATIONAL
High-dose ubiquinol — MSA	Mitochondrial CoQ10 support	Phase 2 RCT (NCT02388295) positive on UMSARS-II (p=0.003); Phase 3 underway	INVESTIGATIONAL
Verdiperstat — MSA	Myeloperoxidase inhibitor	Phase 3 M-STAR (NCT03952806) negative; program discontinued	NEGATIVE
Ampreloxetine — MSA (nOH)	NE reuptake inhibitor	Phase 3 CYPRESS (NCT05696717) failed; program discontinued early 2026	NEGATIVE
Prasinezumab — PD	Anti-alpha-synuclein mAb	Phase 2b PADOVA (NCT04777331) missed primary; proceeding to Phase 3	INVESTIGATIONAL
Exenatide — PD	GLP-1 receptor agonist	Phase 3 Exenatide-PD3 (NCT04232969) negative	NEGATIVE

23. Advanced Therapy Pathways and Patient Selection

DBS candidacy is determined by a multidisciplinary team. Favorable features: a robust, documented levodopa response; disabling motor fluctuations or levodopa-induced dyskinesia not manageable with oral therapy; absence of significant cognitive impairment or dementia; stable psychiatric status; and neuroimaging without severe widespread structural pathology.

Surgical exclusion in MSA. Neither DBS nor MR-guided focused ultrasound is indicated for MSA. The distributed oligodendroglial degeneration is not addressed by stimulation or lesioning, and these procedures carry real risk of accelerating axial decline and worsening dysarthria, dysphagia, and balance. If a patient carrying an MSA diagnosis is referred for DBS or FUS, this should trigger diagnostic re-evaluation rather than surgical scheduling.

24. Prognosis, Palliative Timing, and Care Milestones

MSA follows a rapid, progressive course; median survival is approximately 6–10 years from motor or autonomic onset, with wide individual variation.

Care milestones and prognostic markers:

Postural instability and falls: early frequent falls and need for a walking aid within ~3 years indicate a more rapid course.
Bulbar dysfunction and dysphagia: raise aspiration pneumonia risk, a leading cause of death.
Inspiratory stridor: an independent risk factor for sudden, often nocturnal, death.
Cognitive decline: emerging frontal-executive dysfunction warrants reassessment of decision-making capacity and timely advance care planning.

Palliative care timing: formal palliative care referral is appropriate at diagnosis or within 6–12 months. Structured advance care planning should be revisited at defined trigger points: at diagnosis; at first fall or hospitalization; at onset of dysphagia; at onset of stridor; and when mobility requires a wheelchair.

25. Clinical Pipeline Update (2024–2026)

Key updates in the MSA disease-modification and autonomic-therapy landscape are reflected in the evidence tables above (Section 22). Notable developments:

The Phase 3 MASCOT trial (amlenetug) is the most advanced MSA disease-modification program; headline results are anticipated around 2027.
ATH434 reported the strongest positive Phase 2 signal in MSA to date; Phase 3 anticipated.
The ampreloxetine failure (CYPRESS) was a significant setback for autonomic therapeutics, leaving no new agent in late-stage development for neurogenic OH in MSA.
Alpha-synuclein SAA subtype discrimination is the most consequential recent diagnostic advance: Lewy-fold-specific assays show high sensitivity/specificity for PD/DLB while correctly excluding MSA.
Serum NfL is now widely available as a prognostic and trial-enrichment biomarker.

26. Guideline Concordance and Utah Referral Pathways

The diagnostic recommendations in this guide align with the MDS 2022 MSA diagnostic criteria and the MDS clinical diagnostic criteria for PD. Symptomatic and advanced-therapy recommendations are consistent with AAN and MDS practice guidance. No agent is currently approved as disease-modifying for PD or MSA.

Utah referral pathways: The University of Utah Movement Disorders Program is the regional referral hub. Scheduling: 801-585-7575. Mark referrals “suspected atypical parkinsonism / MSA — needs autonomic workup.” For autonomic evaluation or second opinions beyond Utah: Mayo Clinic (Rochester, Scottsdale) and Vanderbilt Autonomic Dysfunction Center (Nashville).

Appendix A — Supplements in MSA and Parkinsonism

Read before considering any supplement. This appendix is a clinical research summary, not medical advice or a recommendation to take any product. Dietary supplements are not harmless. In MSA the central concern is hemodynamic stability: any supplement that affects blood pressure, vascular tone, or autonomic function carries heightened risk in a population whose blood pressure regulation is already failing. Every supplement should be discussed with the care team, introduced one at a time, and accompanied by blood pressure monitoring. Tell your clinicians about everything you take, including products considered “natural.”

Evidence grades: A strong RCT evidence B moderate (positive Phase 2 or strong observational) C limited or pilot data D preclinical or theoretical only F evidence of harm or contraindication in MSA

Supplement	Grade	Evidence Summary and MSA Considerations
CoQ10 / Ubiquinol	B	The only supplement with a positive MSA-specific controlled trial. A multicenter, double-blind Phase 2 RCT (n=139) of ubiquinol 1,500 mg/day for 48 weeks was positive on UMSARS Part II. A Phase 3 trial is underway. Does not worsen OH. Use the reduced form (ubiquinol) for bioavailability. May reduce warfarin effect. Phase 3 pending: not an established therapy.
Melatonin	B+	Triple benefit in MSA: (1) first-line for RBD, preferred over clonazepam; (2) under active trial for reducing nocturnal/supine hypertension; (3) preclinical neuroprotection. Does not worsen OH. Start 3 mg, titrate to 6–12 mg extended-release at bedtime.
Mucuna pruriens	F (MSA)	Dangerous in MSA — avoid. A natural levodopa source containing no carbidopa; unpredictable dosing (commercial products found to contain 228–2,186% more levodopa than labeled). Directly antagonizes midodrine and droxidopa.
Creatine	A– (NEG)	The large NET-PD LS-1 trial (n=1,741) found no slowing of PD progression. No MSA rationale.
Vitamin E (high-dose)	A– (NEG)	The DATATOP trial found no disease-modifying benefit in PD. High-dose (>400 IU/day) associated with increased all-cause mortality.

Supplement	Grade	Notes and MSA Considerations
R-Alpha-lipoic acid	C+	Potentially beneficial — specialist supervision required. Corrected OH in 66% of patients in a non-MSA cohort without worsening supine hypertension. Start low (300 mg), titrate to 600 mg with BP monitoring under autonomic specialist. Do not self-medicate.
Omega-3 fatty acids	C	Anti-inflammatory rationale; no RCT showing disease modification. Generally safe; mild antiplatelet effect at high doses.
N-Acetylcysteine (NAC)	C–	Small open-label PD signals; low oral bioavailability. May have antihypertensive properties — concern in neurogenic OH. No MSA-specific data.
Curcumin / Turmeric	D	Negligible bioavailability without piperine. Piperine inhibits multiple CYP enzymes, altering MSA medication levels. Hepatotoxicity flagged. Not recommended in MSA.
Resveratrol	D	Mild vasodilator that could worsen OH. Not recommended.
EGCG / Green tea extract	D	High-dose associated with acute liver injury; PD trial showed no benefit. Avoid concentrated extracts; ordinary tea drinking is fine.
Ginkgo biloba	D	Vasodilatory (can worsen OH), antiplatelet (bleeding risk), CYP-inhibiting. Not recommended in MSA.
Ashwagandha	D	Unpredictable BP effects, hepatotoxicity, immunostimulatory. Avoid in MSA.

Supplement	Target	Notes
Vitamin D	Falls, bone health	Recommended. Deficiency near-universal in MSA. Test 25-OH-D; target ~40–60 ng/mL; 1,000–2,000 IU/day. No significant interactions.
Probiotics	Constipation, levodopa absorption	Grade B — recommended adjunct. The SymPD RCT (2025) was positive for constipation, reduced inflammation, and shortened levodopa time-to-on. Very safe.
Magnesium	Constipation, cramps, sleep	Grade B for constipation (osmotic effect). Magnesium oxide 400–800 mg or citrate 200–400 mg. Avoid in renal impairment.
Psyllium / fiber	Constipation	Grade A — recommended. Core component of MSA bowel management. Take with adequate fluid; separate from medications by 1–2 hours.
Iron	Documented deficiency only	Supplement only for documented iron-deficiency anemia. Do not take to “help” MSA based on ATH434 news. Iron impairs levodopa absorption.

The autonomic vulnerability of MSA makes this list more conservative than an equivalent list for typical Parkinson’s.

Supplement	Risk	Reason to Avoid in MSA
Mucuna pruriens	High	Unregulated natural levodopa without carbidopa; worsens OH; antagonizes pressors.
5-HTP	High	Scleroderma-like syndrome reported with carbidopa. Serotonin syndrome risk with SSRIs/SNRIs. Contraindicated with carbidopa-containing regimens.
St. John’s Wort	High	Potent CYP3A4 inducer — reduces fludrocortisone, amantadine levels. Serotonin syndrome risk.
Ginkgo biloba	High	Vasodilation worsens OH; antiplatelet bleeding risk; CYP inhibition.
Kava	High	Severe hepatotoxicity risk; sedation compounds fall risk.
EGCG / concentrated green tea extract	High	Acute liver injury risk; PD trial showed no benefit.
Comfrey, chaparral, pennyroyal, germander	High	Known hepatotoxins. Absolute avoidance.
Unregulated stem-cell products	High	Unproven; risk of infection, immune reaction, tumor formation. Cell-based therapy belongs only within approved clinical trials.

Early MSA (Diagnosis to ~2 Years)

Test and supplement vitamin D; start melatonin if RBD is present; begin proactive fiber for constipation; ubiquinol is reasonable if the patient wishes to try it (discuss with care team). Establish a home BP monitoring routine. Avoid mucuna pruriens, ginkgo, and unsupervised alpha-lipoic acid.

Middle MSA (~2–5 Years)

Continue the above; consider adding magnesium and a multi-strain probiotic for constipation, and omega-3 for general support. As dysphagia develops, reassess every supplement’s delivery form (large capsules may become unsafe). The supplement list should shrink, not grow.

Advanced MSA (~5+ Years)

Simplify radically. Continue only supplements with clear symptomatic benefit (melatonin for RBD, vitamin D, fiber or magnesium). If a feeding tube is in place, consult a pharmacist on compatibility and use liquid forms.

Glossary

Term	Plain-Language Meaning
Alpha-synuclein	A protein that, when it misfolds and clumps, drives Parkinson’s, MSA, DLB, and PAF — the alpha-synucleinopathies.
Antecollis	Marked forward bending of the neck; a supportive feature of MSA.
Ataxia	Loss of coordination and balance; the defining feature of cerebellar-type MSA (MSA-C).
Autonomic nervous system	The body’s automatic control of blood pressure, bladder, bowel, sweating, and sexual function.
Bradykinesia	Slowness of movement; a core feature of parkinsonism.
Dysarthria	Slurred or effortful speech from impaired muscle control.
Dysphagia	Difficulty swallowing.
Glial cytoplasmic inclusions	Clumps of misfolded alpha-synuclein inside oligodendrocytes — the defining pathology of MSA.
Levodopa	The main medicine for Parkinson’s motor symptoms; the brain converts it into dopamine.
Lewy bodies	Clumps of alpha-synuclein inside neurons — the pathology of PD and DLB (contrast with MSA).
Neurogenic orthostatic hypotension	A sustained drop in blood pressure on standing caused by autonomic nerve failure, with an inadequate compensatory heart-rate rise.
Oligodendrocyte	A brain support cell that insulates nerve fibers; the cell primarily affected in MSA.
Post-void residual	The amount of urine left in the bladder after voiding; high values signal incomplete emptying.
Seed amplification assay (SAA)	A laboratory test that detects misfolded alpha-synuclein in spinal fluid or skin.
Stridor	A harsh, high-pitched sound on breathing in; a serious warning sign in MSA.
Supine hypertension	High blood pressure while lying flat — the counterpart problem to orthostatic hypotension in MSA.
UMSARS	Unified MSA Rating Scale; a standardized measure of MSA severity used in clinics and trials.

Selected References

The items below are starting points for further reading. Bibliographic details should be verified against current primary sources; trial results and approvals evolve.

Wenning GK, et al. The Movement Disorder Society criteria for the diagnosis of multiple system atrophy. Mov Disord. 2022.
Postuma RB, et al. MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord. 2015.
American Academy of Neurology practice guidance on the diagnosis and motor-symptom management of early Parkinson’s disease.
Wenning GK, et al. The natural history of multiple system atrophy — cohort and meta-analytic data on survival.
Athauda D, et al. Exenatide in Parkinson’s disease (Exenatide-PD3 Phase 3 trial). 2025.
Tsuji S, et al. Ubiquinol in multiple system atrophy: a Phase 2 randomized controlled trial. eClinicalMedicine. 2023.
Reports of the Phase 3 M-STAR (verdiperstat) and CYPRESS (ampreloxetine) trials in MSA.
Alterity Therapeutics ATH434 Phase 2 study reports in multiple system atrophy.
Coon EA, et al. Management of orthostatic hypotension in autonomic failure.
SymPD trial: multi-strain probiotic for constipation in Parkinson’s disease. Mov Disord. 2025.
MSA Coalition. Patient and caregiver resources. multiplesystematrophy.org.

Final disclaimer. This addendum guide is an educational research summary. It is not medical advice and does not establish a clinician–patient relationship. It does not replace individualized assessment by a qualified movement-disorders specialist and multidisciplinary team. Medicine evolves rapidly: diagnostic criteria, dosing, trial results, and regulatory approvals stated here reflect evidence current to early 2026 and may later change — verify against current primary sources. For urgent symptoms — stridor, fainting, choking, inability to pass urine, rapid decline — seek immediate medical care.

An accurate diagnosis, proactive multidisciplinary care, and attention to safety change how this journey feels. There is a great deal that can be done — and no one should have to navigate it alone.